钠-葡萄糖共转运蛋白2抑制剂缓解代谢压力

Sodium.glucose cotransport 2 inhibitors ameliorate the ＂metabolic stress＂

由于能量摄入过剩促使2型糖尿病患病率迅速增长。新型降糖药物钠．葡萄糖共转运蛋白2（SGLT-2）抑制剂通过抑制肾脏近曲小管的葡萄糖重吸收，直接排出过剩的能量，从而在整体水平上缓解这种能量过剩所产生的代谢压力。代谢压力的缓解进一步改善血糖、血脂、血压，改善胰岛素抵抗与胰岛B细胞功能，从而使心血管与肾脏获益。

Energy intake excess in modern society contributes to the abrupt increase of type 2 diabetes. The sodium-glucose cotransport 2 （ SGLT-2 ） inhibitors, a new class of hypoglycemic agents inhibit reabsorption of glucose and excrete excessive energy by the kidney and therefore ameliorate the metabolic stress. The relief of metabolic stress further improves blood glucose, lipid levels, so as blood pressure, insulin resistance and pancreatic β cell function, which would he associated with the protection of cardiovascular diseases and amelioration of renal function.